Childhood cough variant asthma and its relationship to classic asthma

Todokoro, Makoto; Mochizuki, Hiroyuki; Tokuyama, Kenichi; Morikawa, Akihiro

doi:10.1016/s1081-1206(10)61871-6

Cited by 32 publications

(24 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…NAEB was diagnosed in 33% of our seropositive patients, and no members of this group became asthmatic. Lai et al (2006) and Todokoro et al (2003) reported CVA in 13.6% and 75%, respectively, of their cases with chronic cough. Lai et al (2006) and Todokoro et al (2003) reported CVA in 13.6% and 75%, respectively, of their cases with chronic cough.…”

Section: Seroprevalence For Toxocara and Chronic Coughmentioning

confidence: 91%

“…Although CVA seems to be more prevalent in Far Eastern countries, it is also an important entity in Europe, especially as regards the differential diagnosis of children with chronic cough (Bateman et al, 2008). Thirty to 54% of those with CVA develop typical asthma within several years (Todokoro et al, 2003;Fujimara et al, 2005). Thirty to 54% of those with CVA develop typical asthma within several years (Todokoro et al, 2003;Fujimara et al, 2005).…”

Section: Seroprevalence For Toxocara and Chronic Coughmentioning

confidence: 99%

See 1 more Smart Citation

Toxocariasis associated with chronic cough in childhood: a longitudinal study in Hungary

et al. 2008

View full text Add to dashboard Cite

Chronic cough lasting 8 weeks or more often seems to be an intractable problem in childhood. Toxocara infection is associated with an increased prevalence of airway symptoms and may be the possible aetiological agent of chronic cough. Of 425 children aged 2-17 years with chronic cough who were investigated for toxocariasis and the distribution of bronchial asthma (BA), cough variant asthma (CVA) and non-asthmatic eosinophilic bronchitis (NAEB), 136 (32%) were seropositive for Toxocara canis antigens. Ninety-three of the 136 were adequately assessed, diagnosed and followed up during 1 year. BA was diagnosed in 40%, CVA in 27% and NAEB in 33% of the children. The eosinophil cell count, serum T. canis IgG levels and symptoms are predictors of the improvement or the decline of the condition. Presuming the aetiopathogenetic role of T. canis in the inflammatory process of chronic cough, we treated the children not only with inhaled corticosteroid (ICS), but also with a 1-week course of anthelminthics. We could significantly decrease the dose of ICS in 23 (62%) of the 37 with BA. The administration of anthelminthics and the avoidance of sensitizers were sufficient for those with NAEB; none needed ICS. ICS therapy could be stopped 2-3 months later in 17 (68%) of the 25 with CVA. We found that 8 of the 25 with CVA (32%) presented asthmatic symptoms at the end of the 1-year period. In Hungary, T. canis may be a potential sensitizer for chronic cough in seropositive children. Deworming therapy will then alleviate the airway symptoms without exacerbation in patients with BA, and have a positive effect on those with NAEB and the majority of those with CVA.

show abstract

Section: Seroprevalence For Toxocara and Chronic Coughmentioning

confidence: 91%

Section: Seroprevalence For Toxocara and Chronic Coughmentioning

confidence: 99%

Toxocariasis associated with chronic cough in childhood: a longitudinal study in Hungary

et al. 2008

View full text Add to dashboard Cite

show abstract

“…In children the age of CVA onset rather than bronchial hyper-responsiveness was found to be a risk factor for typical asthma development [35]. In adults, earlier age of onset and inhaled corticosteroid therapy were found to be predictors of cough remission and wheezing development [36].…”

Section: Cough-variant Asthma: a Precursor Of Typical Asthmamentioning

confidence: 99%

Pharmacotherapy of cough-variant asthma

Antoniu

Mihăescu

Donner

2007

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Cough-variant asthma is considered as an asthma subset in which chronic cough is the only symptom. It is believed to be more frequent and, hence, sometimes overdiagnosed in children, and shares with typical asthma eosinophilic airway inflammation and consequent bronchial hyper-responsiveness. Presently available therapies consist of bronchodilators, inhaled or oral corticosteroids, or leukotriene modifiers. However, the long-term efficacy of these agents in adults and children is not known. This review focuses on current therapies used for cough variant asthma, also highlighting potential therapeutic targets for this condition.

show abstract

“…It is a type of asthma in which the main symptom is a dry, non-productive cough 6 . People with cough-variant asthma or CVA often have no other "classic" asthma symptoms, such as wheezing or shortness of breath.…”

Section: Introductionmentioning

confidence: 99%